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Abstract 
Background: Immune regulation is crucial for the pathogenesis of B-cell acute lymphoblastic leukemia (B-ALL). It has 
been reported that Th17 cells as a newly identified subset of CD4+ T cells are involved in the pathogenesis of several 
hematological disorders. However, the role of Th17 cells in the pathophysiology of B-ALL is still unclear.
Methods: The frequencies of T cells were determined by flow cytometry in the peripheral blood and bone marrow 
of 44 newly diagnosed B-ALL patients and 25 age-matched healthy donors. The cell viability and apoptosis were 
determined by CCK-8 assay and Annexin V staining, respectively. Western blot was applied to identify the level of Akt 
and Stat3 phosphorylation.
Results: We assessed and observed a significantly increased frequency of Th17 cells and a drastically decreased 
frequency of Th1 cells in peripheral blood mononuclear cells and bone marrow mononuclear cells from newly diag-
nosed B-ALL patients compared with healthy donors. Furthermore, increased levels of Th17-related cytokines includ-
ing IL-17, IL-21, IL-23, IL-1β, and IL-6 were presented in between blood and marrow in B-ALL patients. Both IL-17A and 
IL-21, two Th17-secreted cytokines, induced the proliferation of B-ALL cell line Nalm-6 and patient B-ALL cells isolated 
from B-ALL patients, herein either cytokine led to the phosphorylation of Akt and Stat3. Additionally, IL-17A promoted 
resistance to daunorubicin via activation of Akt signaling and the PI3K/Akt inhibitor LY294002 or perifosine almost 
completely rescued daunorubicin-induced cell death in B-ALL cells.
Conclusions: Our findings suggest that elevated Th17 cells secrete IL-17A by which promotes the proliferation and 
resistance to daunorubicin in B-ALL cells through activation of Akt signaling. Th17 cells may represent a novel target 
to improve B-ALL immunotherapy.
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Background
B-cell acute lymphoblastic leukemia (B-ALL) character-
ized by accumulation of immature lymphoid progenitors 
affects both children and adults. Great strides in devel-
opment of effective treatments have led to a cure rate 
of more than 90 % in children, whereas the prognosis of 
adults remains poor [1]. Relapses, treatment resistance 
and serious infections are the leading causes of death 
in most cases. Pro-survival signals provided by tissue 
microenvironments, such as intricate crosstalk between 
B-ALL cells and CD4+ T cells, mesenchymal stromal 
cells, and various cytokines, contribute to maintain leu-
kemic clones and promote resistance to chemotherapy in 
adult B-ALL patients [2].
Undoubtedly, immune dysfunction occurs in the bone 
marrow (BM) microenvironment of patients with B-ALL 
due to abnormal infiltrations of several immune cells. As 
one of the most important immune cells, CD4+ T cells 
are vital in the induction and control the differentiation 
of other immune cells in response to tumor-specific anti-
gens and play a central role in initiating, regulating, and 
maintaining immune responses against cancer. Th1 cells 
produce interferon-γ (IFN-γ) and predominantly pro-
mote cell-mediated immunity, whereas Th2 cells secrete 
IL-4, IL-5 and IL-13. Th17 cells, named for their signa-
ture production of IL-17A, also secrete IL-17F, IL-21, and 
IL-22, thereby inducing an enormous tissue reaction due 
to the broad distribution of the IL-17 and IL-21 receptors 
and exerting a crucial role in the development of inflam-
matory and autoimmune diseases [3–6]. In addition, 
Th17 cells are implicated in many cancers, but their role 
in cancer has not been well elucidated and remains under 
debate [7–10]. It is now well accepted that Th1 cells and 
their secreted signature cytokine IFN-γ exhibit robust 
anti-tumor activity [11, 12]. Several studies have shown 
that IFN-γ inhibits Th17 cell differentiation and IL-17 
inhibits Th1 cell differentiation and IFN-γ production 
[7, 13–15], suggesting that Th1 and Th17 cells appear to 
have a reciprocal relation in function. Therefore, it makes 
sense to investigate the interplay of Th1 and Th17 cells 
in the tumor microenvironment. B-ALL represents an 
ideal model to assess the crosstalk between tumor and 
the immune system as the disease is usually widely dis-
seminated, so that immune cells in the peripheral blood 
(PB) and BM are in close contact with B-ALL cells. The 
immune system fails to identify and eliminate B-ALL 
cells, by which contributes to the development of B-ALL.
In the present study, we demonstrate that elevated fre-
quencies of Th17 cells and Th17-related cytokines and 
reduced frequencies of Th1 cells are presented in PB 
and BM from B-ALL patients; Th17-secreted cytokines 
IL-17A and IL-21 activate the Akt signaling and Stat3 
signaling, and subsequently stimulate the proliferation in 
B-ALL cell line Nalm-6 and primary B-ALL cells; IL-17A 
also promotes resistance to daunorubicin through activa-
tion of Akt signaling.
Methods
Patients and samples
A total of 44 patients with newly diagnosed B-ALL (age 
range 15–68  years, median age 33  years) were enrolled 
in this study from July 2009 and February 2015 in our 
center. All patients with B-ALL were diagnosed accord-
ing to the World Health Organization classification sys-
tem [16]. Twenty-five age-matched healthy donors for 
control were simultaneously enrolled in this study. This 
study was approved by the Institutional Review board of 
the First Affiliated Hospital of Wenzhou Medical Uni-
versity and informed consent was obtained from all par-
ticipants in accordance with the Declaration of Helsinki 
protocol.
Flow cytometric analysis
The frequencies of Th17 cells and Th1 cells were ana-
lyzed as previously described [7]. Briefly, peripheral 
blood mononuclear cells (PBMCs) and bone marrow 
mononuclear cells (BMMCs) from B-ALL patients and 
healthy donors were stimulated with 40  ng/ml phorbol 
12-myristate13-acetate (PMA) and 1  μg/ml ionomycin 
for 5 h in the presence of 1 μg/ml brefeldin A (BFA; all 
from Sigma-Aldrich, St.louis, MO, USA). The cells were 
subsequently surface stained with a combination of 
PerCP-conjugated anti-CD3 and FITC-conjugated anti-
CD8, fixed and permeabilized and intracellularly stained 
with PE-conjugated anti-IL-17A and APC-conjugated 
anti-IFN-γ (all from BD Biosciences, San Jose, CA, USA). 
Stained cells were acquired and analyzed using CellQuest 
software on a FACSCalibur instrument (BD Biosciences).
ELISA for cytokine measurements
The plasma samples were obtained from PB and BM after 
centrifugation and stored at −80  °C until used. Human 
IL-17 and IL-21 were assayed using ELISA kits purchased 
from BioLegend (San Diego, CA, USA) with the assay 
sensitivities of 2.0 and 16.0  pg/ml, respectively. Human 
IL-23, IL-1β, and IL-6 were measured using ELISA kits 
purchased from R&D systems (Minneapolis, MN, USA) 
with the assay sensitivities of 15.0, 1.0, and 0.7  pg/ml, 
respectively.
Quantitative RT‑PCR for gene expression analysis
Total RNA was extracted from mononuclear cells using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and was 
subsequently reverse transcribed into cDNA accord-
ing to the manufacturer’s guidelines. Then, quantitative 
PCR was performed using SYBR Green PCR master mix 
Page 3 of 11Bi et al. J Transl Med  (2016) 14:132 
(TaKaRa, Dalian, China) with respective primer pairs 
(for primers sequences, see Additional file 1: Table S1) in 
triplicate on an ABI 7500 Real-Time instrument. Expres-
sion data were normalized to GAPDH as an endogenous 
control and the relative expression levels were evaluated 
using the 2−ΔΔCt method.
Cell Counting Kit‑8 (CCK‑8) assay and apoptosis assay
CD19+ cells were isolated from PBMCs or BMMCs of 
B-ALL patients (thereafter as patient B-ALL cells) using 
B Cell Isolation Kit II (Miltenyi Biotec, Bergisch Glad-
bach, Germany) according to the manufacture’s proto-
cols. B-ALL cell line Nalm-6 was a gift from Dr. Chiqi 
Chen (School of Medicine, Jiaotong University, Shanghai, 
China). After Nalm-6 cells and patient B-ALL cells were 
treated or untreated with IL-17, IL-21 (both from Pep-
rotech, Rocky Hill, NJ, USA), daunorubicin, LY294002 
or perifosine (Selleck Chemicals, Houston, TX, USA), 
the cell viability and apoptosis were measured. The cell 
viability was determined using CCK-8 assay (Dojindo, 
Kumamoto, Japan) according to the manufacturer’s 
instruction. The absorbance was read at 450  nm using 
an ELISA reader (ELx800; Bio-Tek Instruments, Win-
ooski, VT, USA). The apoptosis was determined using the 
Annexin V binding assay as previously described [17].
Western blot assays
Western blot analysis was performed as previously 
described [18, 19]. Briefly, after treatment with IL-17A 
or IL-21, Nalm-6 cells and patient B-ALL cells were 
collected, lysed, and further subjected to western blot 
with antibodies specific for phospho-Akt (Ser473), Akt, 
GAPDH (Cell Signaling Technology, Beverly, MA, USA), 
phospho-Stat3 (Tyr705), or Stat3 (Bioworld Technology, 
St.Louis Park, MN, USA), respectively.
Induction assay
CD4+ T cells were isolated from PBMCs of B-ALL 
patients using CD4+ T cell isolation kit (Miltenyi Biotec) 
according to the manufacturer’s instructions. CD4+ T 
cells (2 × 105) were cultured in 1 ml of complete medium 
in 48-well plates stimulated with plate-bound anti-CD3 
antibody (OKT3, 4  μg/ml; eBioscience, San Diego, CA, 
USA) and IL-2 (300 units/ml) with or without Nalm-6 
cells. After 14  days, Th17 cells were determined after 
stimulation with PMA and ionomycin in the presence of 
BFA.
Statistical analysis
Data are presented as mean ± SEM, and statistical analy-
ses were performed by a one-way analysis of variance or 
Mann–Whitney test. P values less than 0.05 were consid-
ered statistically significant.
Results
Increased Th17 cells and decreased Th1 cells in B‑ALL 
patients
Th17 cells have been reported to be enriched in hemato-
logical malignancies including acute myeloid leukemia, 
multiple myeloma, and T-cell acute lymphoblastic leu-
kemia [7, 15, 20, 21]. To investigate whether Th17 cells 
are also enriched in B-ALL, we evaluated the frequency 
of Th17 cells based on cytokine patterns after in  vitro 
stimulation with PMA plus ionomycin in short-term 
culture. As shown in Fig.  1a, b, the frequencies of Th17 
cells were 3.5  ±  0.46  % in B-ALL PBMCs compared 
with 1.8  ±  0.21  % in healthy donor PBMCs (P  <  0.01), 
and 3.2  ±  0.32  % in B-ALL BMMCs compared with 
1.4 ±  0.26  % in healthy donor BMMCs (P  <  0.01), sug-
gesting that Th17 cells are highly enriched in both PB and 
BM from B-ALL patients. We simultaneously analyzed 
the frequency of Th1 cells and found that the frequency of 
Th1 cells was significantly decreased in both PBMCs and 
BMMCs from B-ALL patients compared with those from 
healthy donors (Fig. 1a and b). Quantitative RT-PCR was 
used to measure the mRNA levels of IL-17A and IFN-γ 
in both PBMCs and BMMCs and found that increased 
expression of IL-17A and decreased expression of IFN-γ 
were presented in both PBMCs and BMMCs from B-ALL 
patients compared with those from healthy donors 
(Fig. 1c). Taken together, these findings suggest that Th17 
cells are increased and Th1 cells are decreased in both PB 
and BM from B-ALL patients. Furthermore, when B-ALL 
patients achieved complete remission, the frequencies 
of Th17 cells were markedly decreased in BM compared 
with those from previously untreated patients (Fig. 1d).
(See figure on next page.) 
Fig. 1 Th17 cells increase with reduced Th1 cells in freshly isolated PBMCs and BMMCs from patients with B-ALL. a PBMCs and BMMCs were 
separated and stimulated with PMA and ionomycin for 5 h in the presence of brefeldin A and subsequently stained with antibodies against CD3, 
CD8, intracellular IL-17A or IFN-γ. Flow cytometric analysis was used to determine the Th17 and Th1 cell frequencies. Representative dot plots using 
matching peripheral blood and bone marrow samples from B-ALL patients and healthy donors (HD) were shown. b Statistical data for frequencies 
of Th17 and Th1 cells within CD4+ T population were shown. c Total RNA was extracted from CD4+ T cells isolated from B-ALL patients and HDs and 
reverse transcribed into cDNA and subsequently determined for IL-17A and IFN-γ mRNA expression using quantitative PCR. d The frequencies of 
Th17 cells were significantly decreased in BM when B-ALL patients achieved complete remission (CR). e CD4+ T cells were cultured with or without 
Nalm-6 cells for 14 days in the presence of OKT3 plus IL-2 (300 units/ml). Then, frequencies of Th17 cells were determined after stimulation with PMA 
plus ionomycin
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Because increased Th17 cells were presented in 
B-ALL patients, we next investigated whether B-ALL 
cells drive the expansion of Th17 cells. We cultured 
bulk CD4+ T cells from B-ALL patients in the presence 
of IL-2 in OKT3-coated plates with or without Nalm-6 
cells. As shown in Fig. 1e, the percentage of Th17 cells 
increased in CD4+ T cells cultured with Nalm-6 cells in 
the presence of OKT3 plus IL-2, whereas the percentage 
of Th17 cells decreased in CD4+ T cells cultured with 
OKT3 plus IL-2. These data indicate that the expansion 
of Th17 cells may be attributed to the interplay with 
B-ALL cells.
Th17 cell‑related cytokines in B‑ALL patients
IL-17A is the signature cytokine secreted by Th17 cells 
and contributes to Th17-mediated diseases. IL-21 is pro-
duced by Th17 cells and promotes or sustains Th17 lin-
eage commitment [22]. IL-23, IL-1β, and IL-6 regulate 
the establishment and clonal expansion of Th17 cells. 
To further confirm elevated existence of Th17 cells in 
B-ALL patients, we measured the levels of Th17-related 
cytokines. We observed significant increases in levels 
of plasma IL-17A and IL-21 in PB and BM from newly 
diagnosed B-ALL patients compared with those from 
healthy donors (Fig.  2a and b). Higher levels of IL-23, 
IL-1β, and IL-6 were also observed in PB and BM from 
B-ALL patients compared with those from healthy 
donors (Fig. 2c–e). Taken together, these findings suggest 
that elevated Th17 cells appear to exist in the PB and BM 
microenvironment in B-ALL patients.
Two Th17‑related cytokines, IL‑17A and IL‑21, promote 
the proliferation of B‑ALL cells via activation of the Akt 
and Stat3 signaling
As Th17 cells secrete a variety of cytokines, including 
IL-17A, IL-17F, IL-21, and IL-22, their effects on B-ALL 
Fig. 2 The levels of Th17-associated cytokines were increased in PB and BM samples from patients with B-ALL. The PB and BM samples were 
aspirated from B-ALL patients and healthy donors (HD) and determined for the levels of IL-17 (a), IL-21 (b), IL-23 (c), IL-1β (d), and IL-6 (e) using ELISA. 
Statistical data were expressed as mean ± SEM
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cells could be attributed to the actions of any one or a 
combination of these cytokines. We have demonstrated 
that B-ALL cell line Nalm-6 promotes the differentiation 
and expansion of Th17 cells (Fig.  1e), which evokes our 
interest to investigate whether Th17 cells have a mutual 
effect on B-ALL cells. As shown in Fig. 3a and b, IL-17A 
potently promoted the proliferation of patient B-ALL 
cells and Nalm-6 cells. IL-21, another main cytokine 
secreted by Th17 cells, also promoted the proliferation of 
patient B-ALL cells and Nalm-6 cells (Fig.  3c and d). It 
has been reported that interleukins exert their effects via 
specific cell surface receptors. Therefore, we measured 
the expression of IL-17 receptor A (IL-17RA) and found 
that the IL-17RA was weakly expressed on patient B-ALL 
cells and Nalm-6 cells (Fig. 3e). We used anti-IL-17R anti-
body to further determine the effect of IL-17RA signaling 
in IL-17-induced B-ALL cell proliferation. As shown in 
Fig. 3f, although anti-IL-17R antibody alone did not sig-
nificantly affect cell viability, it significantly inhibited the 
proliferation of B-ALL cells in the presence of IL-17A.
Both the PI3K/Akt and Jak2/Stat3 signaling have been 
shown to play pivotal roles in tumor cell proliferation, 
survival, invasion and immunosuppression in many 
tumors including leukemia [23, 24]. Therefore, we ana-
lyzed these two signalings in B-ALL cells stimulated with 
IL-17A or IL-21. As shown in Fig.  3g and h, IL-17A or 
IL-21 stimulation promoted the phosphorylation of Akt 
and Stat3 in Nalm-6 cells. These findings indicate that 
Th17 cells exhibit a pro-tumor effect on B-ALL cells 
through secreting IL-17 and IL-21.
IL‑17A promotes resistance to daunorubicin via activation 
of the Akt signaling
We had demonstrated above that IL-17A promoted the 
proliferation of B-ALL cells through activation of the Akt 
signaling (Fig. 3). As the PI3K/Akt signaling is implicated in 
resistance to anthracycline-based therapies [25], we tested 
whether IL-17A mediates resistance to daunorubicin, a 
chemotherapeutic drug for the treatment of B-ALL. Thus, 
Nalm-6 cells and patient B-ALL cells were pre-incubated 
with IL-17A and subsequently treated with daunorubicin. 
As shown in Fig.  4a and b, IL-17A treatment attenuated 
daunorubicin-induced cytotoxicities in Nalm-6 cells and 
patient B-ALL cells. Specifically, IL-17A also suppressed 
daunorubicin-induced apoptosis (Fig.  4c, d; Additional 
file 2: Figure S1, Additional file 3: Figure S2). To delineate 
the role of PI3K/Akt signaling in IL-17A-mediated resist-
ance to daunorubicin, we treated these cells with the PI3K/
Akt inhibitor LY294002 or perifosine. LY294002 or peri-
fosine could abrogate IL-17A-mediated protection from 
daunorubicin-induced cell death in Nalm-6 cells whereas 
these two PI3K/Akt inhibitors alone almost did not affect 
cytotoxicity (Fig. 5a, b). LY294002 or perifosine also abro-
gated resistance to daunorubicin in patient B-ALL cells 
induced by IL-17A (Fig. 5c, d). Taken together, these data 
suggest that IL-17A protects from daunorubicin-induced 
cell death through activation of the Akt signaling.
Discussion
Th17 cells contribute to protection against fungal and 
parasitic infections and participate in various inflam-
matory and autoimmune diseases. Furthermore, Tar-
geted IL-17 depletion has already been accepted as a 
therapeutic strategy and is now being tested in clinical 
trials for several human autoimmune diseases [26, 27]. 
Whether Th17 cells and IL-17 also play similar roles in 
tumor pathogenesis and progression deserves further 
study. Here we demonstrate that increased Th17 cells and 
decreased Th1 cells are presented in PB and BM from 
B-ALL patients. IL-17A or IL-21, two cytokines mainly 
produced by Th17 cells, can promote the proliferation of 
B-ALL cells.
The interplay between immune cells and tumor cells 
contributes importantly in the induction of immune tol-
erance and tumor progression at tumor sites. Elevated 
proportions of Th17 cells have been identified in the total 
CD4+ T cell populations in several different human solid 
tumors and hematological malignancies including ovar-
ian, prostate carcinomas, multiple myeloma, and acute 
myeloid leukemia [7, 20, 28, 29]. Abousamra NK et  al. 
[30] have reported that Th17 cells were increased in PB in 
newly diagnosed ALL patients and a significantly longer 
overall survival in patients with high Th17 levels. Simi-
larly, the present study also demonstrated that Th17 cells 
were increased in both PB and BM in newly diagnosed 
patients with B-ALL, a main subtype of ALL [1], indicat-
ing that B-ALL cells secrete critical cytokines required 
for the differentiation and expansion of Th17 cells. Some 
cytokines, such as IL-1β, IL-6, and IL-23, have been 
shown to promote the generation and differentiation of 
human Th17 cells [7]. Higher levels of IL-23, IL-1β, and 
IL-6 were observed in B-ALL patients, suggesting that 
the milieu contributes to the expansion of Th17 cells.
Malignant B cells isolated from B-cell NHL patients 
have been shown to induce the differentiation of regula-
tory T cells in vitro [31]. In the present study, B-ALL cell 
line Nalm-6 also promoted the differentiation and expan-
sion of Th17 cells from CD4+ T cells, similar to ovarian 
tumor cells [28]. Undoubtedly, Th17 cells also secrete 
cytokines to affect B-ALL cells. It has been well identified 
that IL-17A plays an important role in promoting can-
cer growth. The PI3K/Akt and Jak2/Stat3 signaling are 
two important signalings implicated in IL-17A-mediated 
proliferation. In the present study, IL-17A stimulation 
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Fig. 3 IL-17A promotes the proliferation of B-ALL cells via activation of IL-17R signaling. a–d Patient B-ALL cells isolated from 4 B-ALL patients and 
B-ALL cell line Nalm-6 were incubated in the presence or absence of IL-17A (50 ng/ml) or IL-21 (50 ng/ml) for 7 days and then, CCK-8 assay was used 
to assess cell viability. Statistical data representing at least three independent experiments are presented as the viability in the presence of IL-17A 
or IL-21 compared with control. e Representative histograms were presented for the IL-17RA expression of patient B-ALL cells and Nalm-6 cells, 
determined using PE-conjugated anti-CD217 antibody (solid line) or mouse IgG1 antibody (dotted line) by flow cytometry. f Patient B-ALL cells and 
Nalm-6 cells were incubated with or without IL-17A (50 ng/ml) in the presence or absence of anti-IL-17R antibody (3 μg/ml) for 7 days and then, 
the cell viability was determined using CCK-8 assay. g, h Western blot analysis showed the phosphorylation of Akt and Stat3 were prominently 
increased within 2 h in Nalm-6 cells stimulated with IL-17A (50 ng/ml) or IL-21(50 ng/ml). Images representing four independent experiments were 
shown
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promoted the proliferation of B-ALL cells through acti-
vation of Akt and Stat3 signaling. Obviously, blockade 
of IL-17RA signaling almost completely abrogated IL-
17A-induced proliferation in B-ALL cells.
In healthy B cells, IL-21 induces differentiation of naïve 
and memory B cells into antibody-producing plasma 
cells [32]. However, IL-21 exerts diverse effects based 
on the histology of malignant B cells. For example, IL-21 
stimulation induces apoptosis of chronic lymphocytic 
leukemia and diffuse large B-cell lymphoma cells while 
promoting the growth of myeloma and waldenstrom 
macroglobulinemia tumor cells [33–36]. In the present 
study, we focused on the role of IL-21 in B-ALL cells, to 
our knowledge which has not been discussed before. As 
expected, IL-21 promoted the proliferation of Nalm-6 
cells and patient B-ALL cells, suggesting that it should 
work together with IL-17A to facilitate the expansion of 
B-ALL cells. Furthermore, the addition of IL-21 resulted 
in robust phosphorylation of Akt and Stat3 at 15  min 
post-stimulation, implying that the PI3K/Akt and Jak2/
Stat3 signaling have been activated quickly, and these two 
signalings contribute to the proliferation effect.
Daunorubicin as a chemotherapeutic agent has been 
used clinically to treat B-ALL patients for several dec-
ades [37]. Several factors, such as the overexpression of 
microRNA-125b, influence resistance to daunorubicin 
[38], and whether IL-17A is an important factor remains 
unclear. In the present study, IL-17A resulted in resist-
ance to daunorubicin against B-ALL cells, in which 
the Akt signaling play a key role, because a PI3K/Akt 
Fig. 4 IL-17A promotes resistance to daunorubicin. Nalm-6 cells and patient B-ALL cells isolated from 4 B-ALL patients were cultured for 24 h in 
complete medium with or without IL-17A at 50 ng/ml and subsequently supplemented with daunorubicin at 100, 200, or 400 nM as indicated for 
24 h. The cell viability was determined using CCK-8 assay, and apoptosis was determined using Annexin V staining. IL-17A promoted the prolifera-
tion and reduced apoptosis of Nalm-6 cells (a, c) and patient B-ALL cells (b, d). Statistical data representing at least 3 independent experiments 
were shown
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inhibitor LY294002 or perifosine almost blocks the pro-
tective effects of IL-17A.
Conclusions
We found that increased Th17 cells and decreased Th1 
cells were presented in PB and BM from patients with 
B-ALL. IL-17A or IL-21 could promote the proliferation 
of B-ALL cells through activation of Akt and Stat3 sign-
aling. The PI3K/Akt inhibitor LY294002 or perifosine 
almost completely abrogated IL-17A-mediated protec-
tion from daunorubicin-induced cell death in B-ALL 
cells. Therefore all of the above data suggested that 
Th17 cells might serve as a potential target for B-ALL 
immunotherapy.
Additional files
Additional file 1: Table S1. The sequences of the primers used for real-
time qPCR.
Additional file 2: Figure S1. IL-17A reduces apoptosis to daunorubicin 
in Nalm-6 cells. Nalm-6 cells were cultured for 24 h in complete medium 
with or without IL-17A at 50 ng/ml and subsequently supplemented 
with daunorubicin at 100, 200, or 400 nM as indicated for 24 h. Apoptosis 
was determined using Annexin V staining on a flow cytometry. Images 
representing 3 independent experiments were shown.
Additional file 3: Figure S2. IL-17A reduces apoptosis to daunorubicin 
in patient B-ALL cells. Patient B-ALL cells isolated from 4 patients with 
B-ALL were cultured for 24 h in complete medium with or without IL-17A 
at 50 ng/ml and subsequently treated with daunorubicin at 100, 200, or 
400 nM as indicated for 24 h. Apoptosis was measured using Annexin V 
staining on a flow cytometry. Images representing at least 3 independent 
experiments were shown.
Fig. 5 IL-17A-induced resistance to daunorubicin is dependent on Akt activation. Nalm-6 cells (a, b) and patient B-ALL cells (c, d) isolated from 4 
B-ALL patients were pre-treated with the PI3K/Akt inhibitor LY294002 at 10 μM or perifosine at 2 μM for 2 h and treated with or without IL-17A at 
50 ng/ml for 24 h. Then, the cells were further treated with daunorubicin at 200 nM for 24 h. The cell viability and apoptosis were determined using 
CCK-8 assay and Annexin V staining, respectively. Statistical data representing at least three independent experiments were shown
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